Particle shape enhances specificity of antibody-displaying nanoparticles

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 9, 2013, Pages 3270-3275

  Barua, Sutapa ^a   Yoo, Jin Wook ^b   Kolhar, Poornima ^a   Wakankar, Aditya ^c   Gokarn, Yatin R ^c,d   Mitragotri, Samir ^a  

^a Santa Barbara   (United States)

^b Pusan National University   (South Korea)

^c GENENTECH INC   (United States)

^d INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Drug delivery; Morphology; Nanomedicine; Nanotechnology

Indexed keywords

CAMPTOTHECIN; NANOPARTICLE; POLYSTYRENE; TRASTUZUMAB;

ANTIBODY SPECIFICITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL SURFACE; PARTICLE SIZE; PRIORITY JOURNAL; STRUCTURE ANALYSIS; SURFACE PROPERTY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOCYTOSIS; FEMALE; HUMANS; NANOPARTICLES; TEMPERATURE;

EID: 84874460666     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1216893110     Document Type: Article

References (45)

1. Ward ES, Ober RJ (2009) Multitasking by exploitation of intracellular transport functions: The many faces of FcRn. Advances in Immunology, ed Alt FW (Academic, San Diego), 103, pp 77-115.
2. Haab B, Dunham M, Brown P (2001) Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol 2(2):RESEARCH0004.
3. Valadon P, et al. (2010) Designed auto-assembly of nanostreptabodies for rapid tissue- specific targeting in vivo. J Biol Chem 285(1): 713-722.
4. Burris HA, 3rd, et al. (2011) Phase II study of the antibody drug conjugate trastuzumab- DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29(4): 398-405.
5. Emery P, et al. (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. Lancet 372(9636): 375-382.
6. Corren J Anti-interleukin-5 antibody therapy in asthma and allergiesCurr Opin Allergy Clin Immunol(2011) 116565-570, 10.1097/ACI. 1090b1013e32834c32833d32830.
7. Sundberg EJ (2009) Structural basis of antibody-antigen interactions. Methods Mol Biol 524: 23-36.
8. Cuesta ÁM, Sainz-Pastor N, Bonet J, Oliva B, Álvarez- Vallina L (2010) Multivalent antibodies: When design surpasses evolution. Trends Biotechnol 28(7): 355-362.
9. Choi CHJ, Alabi CA, Webster P, Davis ME (2010) Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA 107(3): 1235-1240.
10. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J (2007) Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 120(1-2): 18-26.
11. Sun B, Ranganathan B, Feng S-S (2008) Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 29(4): 475-486.
12. Chen T-J, et al. (2009) Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J Biol Inorg Chem 14(2): 253-260.
13. Wu X, et al. (2003) Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 21(1): 41-46.
14. Gao X, Cui Y, Levenson RM, Chung LWK, Nie S (2004) In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22(8): 969-976.
15. Tsagkogeorgas F, Ochsenkühn-Petropoulou M, Niessner R, Knopp D (2006) Encapsulation of biomolecules for bioanalytical purposes: Preparation of diclofenac antibodydoped nanometer-sized silica particles by reverse micelle and sol-gel processing. Anal Chim Acta 573-574(0): 133-137.
16. Sahoo SK, Labhasetwar V (2005) Enhanced antiproliferative activity of transferrinconjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2(5): 373-383.
17. Napp J, et al. (2011) Targeted luminescent near-infrared polymer-nanoprobes for in vivo imaging of tumor hypoxia. Anal Chem 83(23): 9039-9046.
18. Butler JE, Lü EP, Navarro P, Christiansen B (1997) Comparative studies on the interaction of proteins with a polydimethylsiloxane elastomer. I. Monolayer protein capture capacity (PCC) as a function of protein pl, buffer pH and buffer ionic strength. J Mol Recognit 10(1): 36-51.
19. Gupta B, Torchilin VP (2007) Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol Immunother 56(8): 1215-1223.
20. Steinhauser I, Spänkuch B, Strebhardt K, Langer K (2006) Trastuzumab-modified nanoparticles: Optimisation of preparation and uptake in cancer cells. Biomaterials 27(28): 4975-4983.
21. Shenton W, Davis SA, Mann S (1999) Directed self-assembly of nanoparticles into macroscopic materials using antibody-antigen recognition. Adv Mater 11(6): 449-452.
22. Jiang W, Kim BY, Rutka JT, Chan WC (2008) Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 3(3): 145-150.
23. Zhang S, Li J, Lykotrafitis G, Bao G, Suresh S (2009) Size-dependent endocytosis of nanoparticles. Adv Mater 21(4): 419-424.
24. Slamon DJ, et al. (1987) Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785): 177-182.
25. Clift MJ, Bhattacharjee S, Brown DM, Stone V (2010) The effects of serum on the toxicity of manufactured nanoparticles. Toxicol Lett 198(3): 358-365.
26. Smith PJ, et al. (2012) Cellular entry of nanoparticles via serum sensitive clathrinmediated endocytosis, and plasma membrane permeabilization. Int J Nanomedicine 7: 2045-2055.
27. Nel AE, et al. (2009) Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 8(7): 543-557.
28. Szöllösi J, Balázs M, Feuerstein BG, Benz CC, Waldman FM (1995) ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 55(22): 5400-5407.
29. Gratton SE, et al. (2008) The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 105(33): 11613-11618.
30. Mi Y, Liu X, Zhao J, Ding J, Feng SS (2012) Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers. Biomaterials 33(30): 7519-7529.
31. Wuang SC, Neoh KG, Kang ET, Pack DW, Leckband DE (2008) HER-2-mediated endocytosis of magnetic nanospheres and the implications in cell targeting and particle magnetization. Biomaterials 29(14): 2270-2279.
32. Yousefpour P, Atyabi F, Vasheghani-Farahani E, Movahedi AA, Dinarvand R (2011) Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab. Int J Nanomedicine 6: 1977-1990.
33. Koopaei MN, et al. (2011) Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: Preparation, characterization, and cytotoxicity studies. Int J Nanomedicine 6: 1903-1912.
34. Liu J, Li J, Rosol TJ, Pan X, Voorhees JL (2007) Biodegradable nanoparticles for targeted ultrasound imaging of breast cancer cells in vitro. Phys Med Biol 52(16): 4739-4747.
35. Perelson AS (1981) Receptor clustering on a cell surface. III. Theory of receptor crosslinking by multivalent ligands: description by ligand states. Math Biosci 53(1-2): 1-39.
36. Sulzer B, Perelson AS (1996) Equilibrium binding of multivalent ligands to cells: Effects of cell and receptor density. Math Biosci 135(2): 147-185.
37. Huang Y-F, Liu H, Xiong X, Chen Y, Tan W (2009) Nanoparticle-mediated IgE-receptor aggregation and signaling in RBL mast cells. J Am Chem Soc 131(47): 17328-17334.
38. Piper JW, Swerlick RA, Zhu C (1998) Determining force dependence of two-dimensional receptor-ligand binding affinity by centrifugation. Biophys J 74(1): 492-513.
39. Decuzzi P, FerrariM (2006) The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials 27(30): 5307-5314.
40. Tokuda Y, et al. (1999) Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer 81(8): 1419-1425.
41. Gessner A, Lieske A, Paulke B-R, Müller RH (2003) Functional groups on polystyrene model nanoparticles: Influence on protein adsorption. J Biomed Mater Res A 65(3): 319-326.
42. Albanese A, Tang PS, Chan WCW (2012) The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 14(1): 1-16.
43. Luchini A, Longo C, Espina V, Petricoin EF, 3rd, Liotta LA (2009) Nanoparticle technology: Addressing the fundamental roadblocks to protein biomarker discovery. J Mater Chem 19(29): 5071-5077.
44. Champion JA, Mitragotri S (2006) Role of target geometry in phagocytosis. Proc Natl Acad Sci USA 103(13): 4930-4934.
45. Champion JA, Katare YK, Mitragotri S (2007) Making polymeric micro- and nanoparticles of complex shapes. Proc Natl Acad Sci USA 104(29): 11901-11904.